Page last updated: 2024-09-05

anidulafungin and Candidiasis, Invasive

anidulafungin has been researched along with Candidiasis, Invasive in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	44 (83.02)	24.3611
2020's	9 (16.98)	2.80

Authors

Authors	Studies
Bretagne, S; Desnos-Ollivier, M; Dromer, F; Lortholary, O	1
Mosegui, GBG; Rodrigues, MPDS; Vianna, CMM	1
Bellmann, R; Joannidis, M; Oberacher, H; Schwärzler, B; Welte, R	1
Aram, JA; Carlesse, F; Conte, U; Leister-Tebbe, H; Queiroz-Telles, F; Raber, S; Roilides, E; Swanson, R; Tawadrous, M; Yan, JL	1
Benjamin, DK; Cohen-Wolkowiez, M; Leister-Tebbe, H; Liu, P; McFadyen, L; Raber, S; Swanson, R; Tawadrous, M; Xie, R	1
Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL	1
Castanheira, M; Deshpande, LM; Messer, SA; Pfaller, MA; Rhomberg, PR; Utt, EA	1
Abidi, MZ; Crowther, B; Gleason, T; Gray, A; Grazia, TJ; Porter, K; Sartain, E; Schoeppler, K; Smith, JB; Steele, M	1
Aram, J; Capparella, MR; Conte, U; Garbino, J; Herbrecht, R; Kullberg, BJ; Mootsikapun, P; Nucci, M; Paiva, JA; Schlamm, H; Swanson, R; Vasquez, J; Yan, JL	1
Aram, J; Bassetti, M; Capparella, MR; Hogan, PA; Kontoyiannis, DP; Nucci, M; Yan, JL	1
Charbonneau, C; Chen, YC; Lee, TY; Ou, HT	1
Dinleyici, EC; Kara, A; Kong, DCM; Neoh, CF; Senol, E; Turner, SJ	1
De Carolis, E; Mello, E; Perlin, DS; Posteraro, B; Sanglard, D; Sanguinetti, M; Vella, A	1
Clancy, CJ; Healey, KR; Kline, EG; Kordalewska, M; Nguyen, MH; Perlin, DS; Shields, RK	1
Aram, JA; Carlesse, F; Conte, U; Leister-Tebbe, H; Liu, P; Queiroz-Telles, F; Roilides, E; Tawadrous, M; Yan, JL	1
Dewaele, K; Frans, J; Ho, E; Lagrou, K; Smismans, A; Tollens, T	1
Abreu, P; Colombo, AL; Magana, M; Nucci, M; Petti, M; Sanchez, SP; Schlamm, HT	1
Canbay, AE; Glöckner, A	1
Barrueta, JA; Carlos Pozo Laderas, J; García Vargas, M; Grau, S; Mir, N; Salavert, M	1
Chan, TS; Chim, CS; Gill, H; Hwang, YY; Khong, PL; Kwong, YL; Leung, AY; Lie, AK; Loong, F; Sim, J; Tse, AC; Tse, E	1
Aguilar, G; Azanza, JR; Badenes, R; Belda, FJ; Carbonell, JA; Ferrando, C; Garcia-Marquez, C; Gencheva, G; Gutierrez, A; Marti, FJ; Miñana, A; Navarro, D; Parra, MA; Puig, J; Sadaba, B	1
Biswas, P; Chin-Hong, P; Kett, DH; Pappas, PG; Patterson, TF; Reboli, AC; Reinhardt, J; Swanson, R; Tobin, E; Vazquez, J	1
Bleeker-Rovers, CP; Delsing, CE; Frager, FA; Gresnigt, MS; Kox, M; Kullberg, BJ; Leentjens, J; Monneret, G; Netea, MG; Pachot, A; Pickkers, P; Preijers, F; van de Veerdonk, FL; Venet, F	1
Aguilar, G; Azanza, JR; Badenes, R; Belda, FJ; Carbonell, JA; Delgado, C; Ferrando, C; Hernández, J; Navarro, D; Parra, MA; Puig, J; Sádaba, B	1
Alffenaar, JW; Kosterink, JG; Proost, JH; Rodgers, MG; Uges, DR; van der Werf, TS; van Wanrooy, MJ; Zijlstra, JG	1
Chlebicki, MP; Kwa, AL; Lee, W; Liew, YX; Ngan, CC; Tan, AL; Teo, J; Too, IA	1
Auzinger, G; Charbonneau, C; Graham, CN; Kantecki, M; Knox, HN; Playford, EG; Schlamm, H; Weinstein, D	1
Ge, T; Liao, S; Xu, G; Yang, J; Zhu, L	1
Groeneveld, AB; Rijnders, BJ; van der Geest, PJ; Vonk, AG	1
Groeneveld, AB; Hunfeld, NG; Ladage, SE; van der Geest, PJ	1
Hsueh, PR; Wang, H; Xu, YC	1
Barber, KE; Cretella, D; King, ST; Stover, KR	1
Aigner, M; Lass-Flörl, C; Mayr, A	1
Aram, J; Benjamin, DK; Capparelli, E; Cheifetz, IM; Cohen-Wolkowiez, M; Hope, WW; Kashuba, AD; Liu, P; Moran, C; Piper, L; Smith, PB; Walsh, TJ	1
Tapısız, A	1
Kofla, G; Ruhnke, M	1
Wilke, M	1
Glöckner, A	1
Cartier, S; Chambers, R; Kett, DH; Maschio, M; Reboli, AC; Rotstein, C; Tarallo, M	1
Le Guyader, N; Leverger, G	1
Chen, SC; Kong, DC; Liew, D; Marriott, D; Morrissey, O; Neoh, CF; Slavin, M; Stewart, K	1
Biswas, P; Kett, DH; Pappas, PG; Reboli, AC; Reisman, AL; Rotstein, C; Schlamm, HT; Shorr, AF; Walsh, TJ	1
Bellmann, R; Gustorff, B; Hell, M; Illievich, U; Kratzer, C; Lass-Flörl, C; Moosbauer, W; Nachbaur, K; Perkhofer, S; Schwameis, F; Vogel, W; Von Goedecke, A; Wimmer, P; Zerlauth, U	1
Biswas, P; Kett, DH; Reboli, AC; Reisman, AL; Schlamm, HT; Shorr, AF	1
Auzinger, G	1
Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Wiederhold, NP	1
Auzinger, G; Borges Sá, M; Dimopoulos, G; Grigoras, I; Kantecki, M; Marček, T; Meersseman, W; Menichetti, F; Miller, PJ; Montravers, P; Pachl, J; Paiva, JA; Ruhnke, M; Sganga, G	1
Jaijakul, S; Ostrosky-Zeichner, L; Swanson, RN; Vazquez, JA	1
Alexander, BD; Balch, AH; Hanson, KE; Lease, ED; Perfect, JR; Pfeiffer, CD; Zaas, AK	1
Andes, D; Castanheira, M; Diekema, D; Lepak, A; Pfaller, M	1
Auzinger, G; Dimopoulos, G; Grigoras, I; Kantecki, M; Marček, T; Meersseman, W; Miller, PJ; Montravers, P; Pachl, J; Paiva, JA; Ruhnke, M; Sá, MB; Sganga, G	1
Liu, P	1
Damle, B; Kantecki, M; Liu, P; Meersseman, W; Paiva, JA; Ruhnke, M	1

Reviews

9 review(s) available for anidulafungin and Candidiasis, Invasive

Article	Year
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. Clinical drug investigation, 2021, Volume: 41, Issue:6 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fluconazole; Humans; Neoplasms; Treatment Outcome; Voriconazole	2021
First case of Acta clinica Belgica, 2020, Volume: 75, Issue:3 Topics: Anastomotic Leak; Anidulafungin; Antifungal Agents; Belgium; Candida; Candidiasis, Invasive; Catheter-Related Infections; Central Venous Catheters; Drug Resistance, Fungal; Female; Gastric Bypass; Humans; Ileum; Intestinal Fistula; Intestinal Perforation; Kuwait; Microbial Sensitivity Tests; Middle Aged; Patient Transfer; Postoperative Complications; Surgical Wound Infection; Urinary Tract Infections	2020
[Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2015, Volume: 110, Issue:2 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Humans; Inactivation, Metabolic; Intensive Care Units; Liver; Liver Diseases; Liver Function Tests; Treatment Outcome	2015
Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future microbiology, 2016, Volume: 11 Topics: Anidulafungin; Antifungal Agents; Asia; Azoles; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidemia; Candidiasis; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Incidence; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Phenotype; Prevalence; Voriconazole	2016
Anidulafungin for the treatment of invasive candidiasis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17 Suppl 1 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Cost-Benefit Analysis; Echinocandins; Fungemia; Humans; Incidence; Intensive Care Units; Randomized Controlled Trials as Topic	2011
Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:3 Topics: Adult; Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis, Invasive; Child; Drug Interactions; Drug Resistance, Fungal; Drug Therapy, Combination; Echinocandins; Humans	2011
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. European journal of medical research, 2011, Apr-28, Volume: 16, Issue:4 Topics: Anidulafungin; Antifungal Agents; Biofilms; Candidiasis, Invasive; Caspofungin; Drug Interactions; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Molecular Structure	2011
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. European journal of medical research, 2011, Apr-28, Volume: 16, Issue:4 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Humans; Lipopeptides; MEDLINE; Micafungin	2011
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature. European journal of medical research, 2011, Apr-28, Volume: 16, Issue:4 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Clinical Trials as Topic; Drug Interactions; Echinocandins; Guidelines as Topic; Humans; Lipopeptides; Micafungin	2011

Trials

14 trial(s) available for anidulafungin and Candidiasis, Invasive

Article	Year
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia. The Pediatric infectious disease journal, 2020, Volume: 39, Issue:4 Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Female; Humans; Infant; Infant, Newborn; Male; Prospective Studies; Treatment Outcome	2020
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies. Mycoses, 2017, Volume: 60, Issue:10 Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis; Candidemia; Candidiasis, Invasive; Clinical Trials as Topic; Echinocandins; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome	2017
A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age. The Pediatric infectious disease journal, 2019, Volume: 38, Issue:3 Topics: Administration, Intravenous; Adolescent; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Internationality; Male; Prospective Studies; Treatment Outcome	2019
An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America. Mycoses, 2014, Volume: 57, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Female; Humans; Latin America; Male; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole; Young Adult	2014
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC infectious diseases, 2014, Feb-21, Volume: 14 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Republic of Korea; Research Design; Risk; Treatment Outcome; United States; Voriconazole; Young Adult	2014
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC infectious diseases, 2014, Mar-26, Volume: 14 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Aspergillosis; Candidiasis, Invasive; Combined Modality Therapy; Echinocandins; Female; Humans; Immunotherapy; Interferon-gamma; Male; Middle Aged; Prospective Studies; Recombinant Proteins	2014
Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study. BMC infectious diseases, 2016, 09-15, Volume: 16 Topics: Anidulafungin; Antifungal Agents; APACHE; Candidiasis, Invasive; Critical Illness; Echinocandins; Female; Humans; Intensive Care Units; Lipopeptides; Liver; Liver Function Tests; Male; Micafungin; Middle Aged; Regression Analysis; Retrospective Studies; Treatment Outcome	2016
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC infectious diseases, 2011, Sep-30, Volume: 11 Topics: Anidulafungin; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Echinocandins; Fluconazole; Humans; Multivariate Analysis; Survival Analysis; Treatment Outcome	2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Critical care (London, England), 2011, Volume: 15, Issue:5 Topics: Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Double-Blind Method; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Severity of Illness Index; Societies, Medical; Treatment Outcome; United States	2011
Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Critical Illness; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Prospective Studies; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole	2012
(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; beta-Glucans; Biomarkers; Candidemia; Candidiasis, Invasive; Echinocandins; Female; Humans; Male; Middle Aged; Proteoglycans; ROC Curve; Treatment Outcome	2012
β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PloS one, 2012, Volume: 7, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; beta-Glucans; Candidiasis, Invasive; Demography; Echinocandins; False Positive Reactions; Feasibility Studies; Female; Humans; Intensive Care Units; Kinetics; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Time Factors; Young Adult	2012
Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive Candida infections: a post hoc analysis. International journal of antimicrobial agents, 2012, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Critical Illness; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Female; Humans; Incidence; Male; Middle Aged; Survival Analysis; Treatment Outcome	2012
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Critical Illness; Echinocandins; Female; Humans; Male; Middle Aged	2013

Other Studies

30 other study(ies) available for anidulafungin and Candidiasis, Invasive

Article	Year
Echinocandins Susceptibility Patterns of 2,787 Yeast Isolates: Importance of the Thresholds for the Detection of FKS Mutations. Antimicrobial agents and chemotherapy, 2022, 05-17, Volume: 66, Issue:5 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Echinocandins; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation	2022
Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo, 2023, Volume: 65 Topics: Anidulafungin; Brazil; Candidemia; Candidiasis, Invasive; Cost-Effectiveness Analysis; Humans	2023
Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020, Feb-15, Volume: 1139 Topics: Anidulafungin; Ascitic Fluid; Candidiasis, Invasive; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Limit of Detection; Linear Models; Micafungin; Reproducibility of Results; Solid Phase Extraction; Spectrophotometry, Ultraviolet	2020
Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. Clinical pharmacology and therapeutics, 2020, Volume: 108, Issue:2 Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Monitoring; Humans; Infant; Infant, Newborn; Male; Middle Aged; Models, Biological; Treatment Outcome; Young Adult	2020
Antifungal drugs work together to treat germs causing fungal infections. Future microbiology, 2021, Volume: 16 Topics: Anidulafungin; Antifungal Agents; Candida auris; Candidiasis, Invasive; Drug Resistance, Fungal; Drug Therapy, Combination; Humans; Nitriles; Pyridines; Triazoles; Voriconazole	2021
Perioperative anidulafungin combined with triazole prophylaxis for the prevention of early invasive candidiasis in lung transplant recipients. Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:4 Topics: Anidulafungin; Candidiasis, Invasive; Humans; Lung; Retrospective Studies; Transplant Recipients; Triazoles	2021
Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. The Journal of antimicrobial chemotherapy, 2017, 08-01, Volume: 72, Issue:8 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Clinical Trials as Topic; Echinocandins; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult	2017
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species. BMC infectious diseases, 2017, 07-10, Volume: 17, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Economics, Pharmaceutical; Fluconazole; Humans; Lipopeptides; Micafungin; Taiwan; Treatment Outcome	2017
Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses, 2017, Volume: 60, Issue:11 Topics: Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Cost-Benefit Analysis; Decision Support Techniques; Double-Blind Method; Echinocandins; Fluconazole; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome; Turkey	2017
Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata. Scientific reports, 2017, 08-22, Volume: 7, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidiasis, Invasive; Drug Resistance, Fungal; Fluconazole; Fungal Proteins; Genetic Fitness; Glucosyltransferases; Humans; Microbial Sensitivity Tests; Microbial Viability; Mutation; Phenotype; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2017
Spontaneous Mutational Frequency and Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidiasis; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Fungal Proteins; Gene Expression; Genetic Loci; Glucosyltransferases; Humans; Micafungin; Microbial Sensitivity Tests; Mutation Rate	2019
Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. Journal de mycologie medicale, 2013, Volume: 23, Issue:3 Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Cost-Benefit Analysis; Echinocandins; Health Care Costs; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Spain	2013
Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. Annals of hematology, 2014, Volume: 93, Issue:3 Topics: Adenine Nucleotides; Adult; Anidulafungin; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Arabinonucleosides; Candida; Candidiasis, Invasive; Caspofungin; China; Clofarabine; Cohort Studies; Cross Infection; Echinocandins; Fusariosis; Fusarium; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Lipopeptides; Lung Diseases, Fungal; Micafungin; Retrospective Studies; Risk Factors	2014
Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6 Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Critical Illness; Echinocandins; Hemodiafiltration; Humans; Intensive Care Units	2014
Pharmacokinetics of anidulafungin during albumin dialysis. Critical care (London, England), 2014, Mar-31, Volume: 18, Issue:2 Topics: Albumins; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Humans; Renal Dialysis	2014
Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:2 Topics: Adult; Aged; Anidulafungin; Bayes Theorem; Candidiasis, Invasive; Critical Illness; Echinocandins; Female; Humans; Male; Middle Aged; Prospective Studies; Young Adult	2015
Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution. BMC infectious diseases, 2015, Jul-03, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candida albicans; Candida glabrata; Candidiasis; Candidiasis, Invasive; Carrier State; Caspofungin; Critical Care; Echinocandins; Female; Fluconazole; Humans; Incidence; Intensive Care Units; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Sensitivity and Specificity; Singapore; Tertiary Care Centers; Voriconazole	2015
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC infectious diseases, 2015, Oct-26, Volume: 15 Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Drug Costs; Echinocandins; Fluconazole; Humans; Intensive Care Units; Length of Stay; Lipopeptides; Micafungin; Models, Economic; Treatment Outcome; United Kingdom	2015
Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients. International journal of antimicrobial agents, 2015, Volume: 46, Issue:6 Topics: Adolescent; Adult; Anidulafungin; Antifungal Agents; Candida; Candidiasis, Invasive; Caspofungin; Child; Child, Preschool; Dose-Response Relationship, Drug; Echinocandins; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Monte Carlo Method	2015
Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections. Mycoses, 2016, Volume: 59, Issue:3 Topics: Administration, Intravenous; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Critical Illness; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Multivariate Analysis; Retrospective Studies	2016
Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp. Journal of medical microbiology, 2016, Volume: 65, Issue:12 Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Respiratory System; Urine	2016
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clinical pharmacology and therapeutics, 2011, Volume: 89, Issue:5 Topics: Age Factors; Anidulafungin; Antifungal Agents; Area Under Curve; Candida; Candidiasis, Invasive; Dose-Response Relationship, Drug; Echinocandins; Female; Humans; Infant; Infant, Newborn; Male	2011
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. PharmacoEconomics, 2011, Volume: 29, Issue:8 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Clinical Trials, Phase III as Topic; Critical Illness; Double-Blind Method; Drug Costs; Echinocandins; Female; Fluconazole; Health Resources; Hospital Costs; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies	2011
[Echinocandins in children]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011, Volume: 18 Suppl 1 Topics: Anidulafungin; Antifungal Agents; Aspergillosis; Aspergillus; Candidiasis, Invasive; Caspofungin; Child; Echinocandins; Evidence-Based Medicine; Humans; Injections, Intravenous; Lipopeptides; Micafungin; Mycoses; Treatment Outcome	2011
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8 Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Australia; Candidiasis, Invasive; Cost-Benefit Analysis; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Models, Statistical; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome	2011
Austrian clinical practice with anidulafungin in 2008: a multicenter survey. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:5 Topics: Anidulafungin; Antifungal Agents; Austria; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Comorbidity; Echinocandins; Female; Humans; Male; Medical Records; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors	2011
Invasive candidiasis following liver transplantation and surgical complications. Mycoses, 2011, Volume: 54 Suppl 4 Topics: Adult; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Echinocandins; Humans; Immunocompromised Host; Liver Failure; Liver Transplantation; Male; Postoperative Complications; Treatment Outcome	2011
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:2 Topics: Anidulafungin; Animals; Antifungal Agents; beta-Glucans; Blood; Blood Chemical Analysis; Candida albicans; Candidiasis, Invasive; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Fluconazole; Mice; Mice, Inbred ICR; Neutropenia; Proteoglycans; Survival Analysis; Treatment Outcome	2012
Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Anidulafungin; Animals; Antifungal Agents; Area Under Curve; Candida glabrata; Candidiasis, Invasive; Caspofungin; Echinocandins; Female; Fungal Proteins; Glucosyltransferases; Humans; Kidney; Lipopeptides; Male; Micafungin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mutation	2012
Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Area Under Curve; Body Weight; Candida; Candidemia; Candidiasis, Invasive; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Echinocandins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome	2013